| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Sangamo BioSciences, Inc., Richmond, California
Angiogenic factors are necessary for tumor proliferation and thus are attractive therapeutic targets. In this study, we have used engineered zinc finger protein (ZFP) transcription factors (TFs) to repress expression of vascular endothelial growth factor (VEGF)-A in human cancer cell lines. We create potent transcriptional repressors by fusing a designed ZFP targeted to the VEGF-A promoter with either the ligand-binding domain of thyroid hormone receptor 
or its viral relative, vErbA. Moreover, this ZFP-vErbA repressor binds its intended target site in vivo and mediates the specific deacetylation of histones H3 and H4 at the targeted promoter, a result that emulates the natural repression mechanism of these domains. The potential therapeutic relevance of ZFP-mediated VEGF-A repression was addressed using the highly tumorigenic glioblastoma cell line U87MG. Despite the aberrant overexpression of VEGF-A in this cell line, engineered ZFP TFs were able to repress the expression of VEGF-A by >20-fold. The VEGF-A levels observed after ZFP TF-mediated repression were comparable to those of a nonangiogenic cancer line (U251MG), suggesting that the degree of repression obtained with the ZFP TF would be sufficient to suppress tumor angiogenesis. Thus, engineered ZFP TFs are shown to be potent regulators of gene expression with therapeutic promise in the treatment of disease.
This article has been cited by other articles:
|
|
 |
|
  J. Y. Lee, B. H. Sung, B. J. Yu, J. H. Lee, S. H. Lee, M. S. Kim, M. D. Koob, and S. C. Kim Phenotypic engineering by reprogramming gene transcription using novel artificial transcription factors in Escherichia coli Nucleic Acids Res., September 1, 2008; 36(16): e102 - e102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-O. Yun, H.-C. Shin, T.-D. Kim, W.-H. Yoon, Y.-A Kang, H.-S. Kwon, S. K. Kim, and J.-S. Kim Transduction of artificial transcriptional regulatory proteins into human cells Nucleic Acids Res., September 1, 2008; 36(16): e103 - e103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Durai, M. Mani, K. Kandavelou, J. Wu, M. H. Porteus, and S. Chandrasegaran Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells Nucleic Acids Res., October 26, 2005; 33(18): 5978 - 5990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-S. Kwon, H.-C. Shin, and J.-S. Kim Suppression of vascular endothelial growth factor expression at the transcriptional and post-transcriptional levels Nucleic Acids Res., April 28, 2005; 33(8): e74 - e74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pages and J. Pouyssegur Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors Cardiovasc Res, February 15, 2005; 65(3): 564 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Blancafort, D. J. Segal, and C. F. Barbas III Designing Transcription Factor Architectures for Drug Discovery Mol. Pharmacol., December 1, 2004; 66(6): 1361 - 1371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tachikawa, O. Schroder, G. Frey, S. P. Briggs, and T. Sera Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins PNAS, October 19, 2004; 101(42): 15225 - 15230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-k. Lee, Y. H. Kim, J.-S. Kim, and W. Seol Induction and characterization of taxol-resistance phenotypes with a transiently expressed artificial transcriptional activator library Nucleic Acids Res., August 10, 2004; 32(14): e116 - e116. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
